Celgene
Celgene bucks trend to strengthen neuroscience pipeline
March 21, 2018Research and Development, Sales and Marketing Alzheimer's, Celgene, Prothena, biotech, drugs, neuroscience, pharma, pharmaceutical
Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion …
Top Ten most popular articles on Pharmafile.com this week
March 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta
After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …
Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory
March 5, 2018Research and Development, Sales and Marketing Cancer, Celgene, Vividion, inflammatory, neurodegenerative, oncology, pharma
Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
FDA refuses to review Celgene’s ozanimod in multiple sclerosis
February 28, 2018Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma
Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …
Celgene reveals strong P3 Otezla data in rare inflammatory condition
February 19, 2018Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma
Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …
Silicon Valley-backed Celgene spin-off launches with $250m
February 16, 2018Medical Communications, Sales and Marketing Celgene, Celularity, biotech, drugs, pharma, pharmaceutical
Biotechs are known for getting off the ground early with serious levels of financing, often based more on the acumen …
Read Pharmafocus January/February 2018 edition online now!
January 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Ablynx, Alex Azr, Celgene, Pharmafocus, Sanofi, UK, artificial intelligence, bioverativ, brexit, juno therapeutics, multiple myeloma, serialisation
With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine …
Celgene Executive Chairman Bob Hugin to retire
January 30, 2018Manufacturing and Production, Medical Communications Bob Hugin, Celgene, pharma
Fresh from its acquisition of Juno Therapeutics, Celgene has announced that its Executive Chairman Bob Hurgin is to retire effective …
Celgene confirms rumours, with $9bn deal for Juno
January 22, 2018Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical
It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …
Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Celgene rumoured to be revving up for Juno buyout
January 17, 2018Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical
Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …
Celgene in $7bn shot on Impact
January 8, 2018Sales and Marketing Celgene, Impact Biomedicines, biotech, drugs, pharma, pharmaceutical
Billions of dollars do not often get put down for drugs that have been dropped by a major pharma company, …
Cancer Research UK agrees largest drug discovery collab to date
December 15, 2017Medical Communications, Research and Development Cancer Research UK, Celgene, biotech, drugs, pharma, pharmaceutical
Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration. …
Celgene hikes price of Revlimid to mask poor Q3 results
October 27, 2017Medical Communications, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical
Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut …
Latest content
FibroFind appoints Lee Borthwick as CEO
